Wilson Sonsini Goodrich & Rosati advised NiKang Therapeutics on the deal. NiKang Therapeutics, an early stage biotech company focused on developing novel small molecule oncology drug…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
